- Home
- ESLA vs SRZN Comparison
ESLA vs SRZN Comparison
Compare ESLA & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESLA
- SRZN
- Stock Information
- Founded
- ESLA 2021
- SRZN 2015
- Country
- ESLA United States
- SRZN United States
- Employees
- ESLA N/A
- SRZN N/A
- Industry
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- ESLA Health Care
- SRZN Health Care
- Exchange
- ESLA Nasdaq
- SRZN Nasdaq
- Market Cap
- ESLA 37.3M
- SRZN 37.7M
- IPO Year
- ESLA N/A
- SRZN N/A
- Fundamental
- Price
- ESLA $0.81
- SRZN $11.86
- Analyst Decision
- ESLA Strong Buy
- SRZN Strong Buy
- Analyst Count
- ESLA 1
- SRZN 2
- Target Price
- ESLA $16.00
- SRZN $38.50
- AVG Volume (30 Days)
- ESLA 47.2K
- SRZN 12.7K
- Earning Date
- ESLA 05-14-2025
- SRZN 05-07-2025
- Dividend Yield
- ESLA N/A
- SRZN N/A
- EPS Growth
- ESLA N/A
- SRZN N/A
- EPS
- ESLA N/A
- SRZN N/A
- Revenue
- ESLA N/A
- SRZN $10,655,000.00
- Revenue This Year
- ESLA $402.53
- SRZN N/A
- Revenue Next Year
- ESLA N/A
- SRZN N/A
- P/E Ratio
- ESLA N/A
- SRZN N/A
- Revenue Growth
- ESLA N/A
- SRZN N/A
- 52 Week Low
- ESLA $0.63
- SRZN $6.00
- 52 Week High
- ESLA $3.23
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- ESLA 38.27
- SRZN 52.87
- Support Level
- ESLA $0.73
- SRZN $10.34
- Resistance Level
- ESLA $1.02
- SRZN $12.93
- Average True Range (ATR)
- ESLA 0.11
- SRZN 1.07
- MACD
- ESLA -0.01
- SRZN -0.01
- Stochastic Oscillator
- ESLA 21.32
- SRZN 45.18
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).